This trial is testing a new drug to see if it's safe and effective for treating lupus nephritis or IgA nephropathy.
- Lupus Nephritis
- IgA Nephropathy
1 Primary · 9 Secondary · Reporting Duration: Week 14, Week 26, and Week 50
4 Treatment Groups
Ravulizumab: LN Cohort
1 of 4
Ravulizumab: IgAN Cohort
1 of 4
Placebo: LN Cohort
1 of 4
Placebo: IgAN Cohort
1 of 4
120 Total Participants · 4 Treatment Groups
Primary Treatment: Ravulizumab · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 75 · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What do we know about Ravulizumab from other scientific research?
"At present, there are 16 ongoing clinical trials researching ravulizumab. Of these, 13 are in phase 3. While several of the trials for ravulizumab are based in Whittier, California, there are 842 locations running clinical trials for ravulizumab globally." - Anonymous Online Contributor
Have there been other tests like this one before?
"Ravulizumab has been researched since 2016. The earliest trial was completed in 2016 and was sponsored by Alexion Pharmaceuticals. Following the first trial in 2016, which involved 270 participants, Ravulizumab received its Phase 3 drug approval. Today there are 16 active studies for Ravulizumab across 193 cities and 31 countries worldwide." - Anonymous Online Contributor
Does this experiment only allow those under 50 to participate?
"This study's requirements for eligible participants are that they must be between 18 and 75 years old. Out of the 567 total clinical trials, 59 are specifically for minors while 508 cater to adults over 65." - Anonymous Online Contributor
How many total hospitals are participating in this research project?
"You can participate in this study at any of the 22 sites, which include locations such as Salt Lake City, S. Gate and Dallas. To limit travel time and inconvenience, please select the site that is closest to you." - Anonymous Online Contributor
Are recruitment and enrollment still ongoing for this research project?
"That is correct. The information on clinicaltrials.gov affirms that this study, which began recruiting on December 11th 2020, is still looking for participants. They are aiming to have 120 patients at 22 different locations." - Anonymous Online Contributor
What are the conditions that ravulizumab has been most effective in treating?
"Ravulizumab is an effective medical intervention for disease activity, and can also help patients that suffer from conditions including hemolysis, thrombotic microangiopathies, atypical hemolytic uremic syndrome." - Anonymous Online Contributor
Has the federal government given its stamp of approval to Ravulizumab?
"Because there is only preliminary data supporting its safety, Ravulizumab was given a score of 2." - Anonymous Online Contributor
How many test subjects are in this experiment?
"That is correct. The clinical trial listing on the website says that this study is actively recruiting patients at 22 locations. They are looking to enroll 120 individuals in total." - Anonymous Online Contributor
Would I be a good candidate for this research?
"Eligible patients for this study must have lupus nephritis, be aged 18-75, and meet the following criteria: being vaccinated against meningococcal infection, having proteinuria ≥1 (gram [g]/day or g/g), clinically active LN that requires/is receiving immunosuppression induction treatment, vaccinated for Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae according to national/local regulatory requirements, diagnosis of active focal or diffuse proliferative LN Class III or IV, diagnosis of primary IgAN, compliance with stable and optimal dose of ren" - Anonymous Online Contributor